Objective: In the seventh edition of TNM Classification of Malignant Tumours (TNM) staging, the stage-IIB category for lung cancer is comprised of four factors: lymph-node metastasis, chest-wall invasion, large tumor size (>7 cm), and same-lobe nodules. Tumors are further classified into eight sub-categories based on each TN factor or factor combinations. This study evaluated the prognostic value of each TN factor or combinations for resected stage-IIB non-small-cell lung cancer (NSCLC). Methods: We retrospectively studied 186 consecutive patients who had resections for NSCLC at Chiba University Hospital and were diagnosed as stage IIB according to the seventh edition of TNM staging. Results: Five-year survivals for each stage IIB were: T2bN1M0 = 47 AE 12% (AE standard error); T3 (chest-wall invasion; N0M0) = 59 AE 7%; T3 (large tumor > 7 cm) = 72 AE 11%; T3 (same-lobe nodules) = 78 AE 5%; T3 (invasion + >7 cm) = 44 AE 16%; T3 (invasion + same-lobe nodules) = 25 AE 22%; T3 (>7 cm + same-lobe nodules) = 0%; and T3 (invasion + >7 cm + same-lobe nodules) = 0%. Among the four single factors, same-lobe nodules had the best prognoses, whereas T2bN1M0 had the worst prognoses. Comparing cases with single factors and multiple factors that decided stage IIB, cases with multiple factors had poorer prognoses (P = 0.02). Conclusion: The stage-IIB category is comprised of eight sub-categories, with either single factors or factor combinations; these sub-categories have different prognoses. The worst survivals were for cases with T2bN1M0 as a single factor or for cases with multiple factors, although these represented a small proportion of resected stage-IIB NSCLC cases. #
Introduction
Lung cancer is the leading cause of death worldwide [1] . TNM Classification of Malignant Tumours (TNM) staging is a predictor of survival and an aid for guiding lung-cancer treatment. The seventh edition of the TNM classification for lung cancer was published in 2009. Several changes were made in the new staging system and they have been supported with regard to prognosis by several studies [2] [3] [4] .
Major changes in this revision for stage IIB included large tumors (>7 cm) and pulmonary metastasis in the same lobe that were sub-categorized into T3 [5] . Then, stage IIB was further classified by four factors: lymph-node metastasis, chest-wall invasion, tumor diameter, and pulmonary metastasis. Theoretically, stage IIB comprises four categories: T2bN1M0, T3 (>7 cm) N0M0, T3 (chest-wall invasion) N0M0, and T3 (same-lobe nodules) N0M0. In addition, eight subgroups are derived, as either single factors alone or factor combinations. Thus, many sub-categories exist for stage IIB that are due to tumor size, invasion, lymph-node metastasis, and pulmonary metastasis. These factors identify different biological profiles of tumor characteristics or behaviors. Further, the new TNM staging system does not provide any direct information for the appropriate treatment for each sub-category, or even each stage.
The aim of this retrospective study was to determine whether these factors resulted in similar prognoses or if single state-of-the-art treatment is sufficient for patients with stage-IIB non-small-cell lung cancer (NSCLC).
Materials and methods

Patients
This retrospective study included 186 patients with pathologic stage-IIB NSCLC, who underwent resections at Chiba University Hospital from January 1990 to December 2007; during this period, 1623 patients underwent resections.
To detect metastasis, Gallium-67 scintigraphy was used through 2002 and 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) was used since 2003. The fifth or sixth TNM staging systems were used during this period. Patients had surgeries by qualified thoracic surgeons by thoracotomies. For all of the patients reviewed, procedures involving more than segmentectomy with lymph-nodal dissection were performed. The patients' clinical records were reviewed to obtain routine demographic information and to confirm the pathology staging. Data extracted from patient's medical record included age, sex, smoking history, tumor histology and location, adjuvant therapies, date of last follow-up, and death from any cause. We obtained informed consent from the patients preoperatively for the use of clinical or molecular data. Our institutional review board approved this retrospective study (Chiba University, IRB No. 204). These patients included 149 (80%) men and 37 (20%) women, who ranged in age from 34 to 87 years (mean AE standard deviation = 66 AE 8.8 years). There were 108 (58%) adenocarcinomas, 65 (35%) squamous cell carcinomas, and 13 (7%) other types of cancers. A total of 13 patients received adjuvant treatments consisting of chemotherapy (N = 9) or radiotherapy (N = 4).
Statistical analysis
Contingency tables were assessed using Fisher's exact test. The Kaplan-Meier method was used to plot survival curves, and a log-rank test was used to evaluate differences between subgroups. Cox proportional hazards regression model was used for multivariate analyses. For each analysis, P < 0.05 was considered significant.
Results
Clinical features of stage-IIB NSCLC patients
All of the possible stage-IIB cases comprised eight subgroups, as shown in Table 1 . Their clinical features are also shown in Table 1 . Survival duration was defined from the date of surgery to the last known date of survival or all-cause death. The follow-up periods ranged from 2 to 206 months (mean/median = 61.8/49.6 months). A total of 112 patients were alive when observations were discontinued and 74 patients had died, of whom 59 patients died because of recurrences and 15 died because of other diseases. All pulmonary resections had been performed with curative intent. Surgical resections included seven pneumonectomies, 11 bilobectomies, 161 lobectomies, and seven segmentectomies. Ten patients received bronchoplasties, four received pulmonary artery reconstructions, and one received a double plasty. In this series, there were no stage-IIB tumors involving the main bronchus that were or were not within 2 cm of the carina (T2bN1M0 or T3N0M0). These cases were accompanied by mediastinal lymph-node involvement and were diagnosed as stage IIIA (T2b-T3N2M0) (data not shown).
Among the single factors, the frequencies of T2bN1M0 and T3 (>7 cm) N0M0 were lower than those of T3 (invasion) N0M0 and T3 (same-lobe nodules) N0M0.
With regard to gender among stage-IIB patients, T3 (invasion) N0M0 cases were more frequent in males than the other sub-category groups (P = 0.007), whereas T3 (samelobe nodules) N0M0 cases were more frequent in females than the other sub-category groups (P < 0.0001). With regard to smoking history, T2bN1M0 and T3 (invasion) N0M0 cases were more frequent among smokers (P = 0.046 and P = 0.001, respectively), while T3 (same-lobe nodules) N0M0 cases were more frequent among never smokers (P < 0.0001). In terms of histology, T2bN1M0 cases were more frequent for squamous cell carcinoma (P < 0.0001), while T3 (same-lobe nodules) N0M0 cases were more frequent for adenocarcinoma (P = 0.03).
Survival analysis
Patients with stage IIB were divided into eight subgroups and survival curves were generated ( Fig. 1(A) , Table 2 ). Among the four subgroups that had single factors for stage IIB, same-lobe nodules had the best prognosis, whereas T2bN1M0 had the worst prognosis. We then re-categorized these eight subgroups into three subgroups: (1) groups A and B (former stage-IIB group), (2) groups C and D (newly staged IIB group), and (3) groups E, F, G, and H (complex stage-IIB group) ( Fig. 1(B) ). These three subgroups had significantly different prognoses (P = 0.006), particularly between the former stage-IIB group and the newly staged IIB group (P = 0.02). Next, there appeared to be survival differences between cases with single factors and those with multiple factors. Therefore, the eight subgroups were re-categorized into two groups: patients with single factors for stage IIB and those with multiple factors for stage IIB (Fig. 1(C) ). Although the number of patients with multiple factors was relatively small (N = 19, 10% of all stage-IIB patients), these patients had poorer prognoses when compared with patients with single factors (P = 0.02).
Finally, we assessed whether the stage-IIB factor was an independent predictor of prognosis compared with major clinical variables by Cox proportional hazards regression analysis ( Table 3 ). The stage-IIB factor was an independent predictor of overall survival for stage-IIB NSCLC patients (P = 0.01).
We compared the effect of adjuvant treatment (chemotherapy or radiotherapy) on overall survival. There was no significant difference between patients' survival with and without adjuvant treatment (P = 0.55).
Discussion
There have been a few reports that analyzed the 5-year survivals of stage-IIB NSCLC patients, who had undergone resections according to the seventh edition of TNM staging. The 5-year survival rate was 36% based on the International Association for the Study of Lung Cancer (IASLC) database [5] , and the 5-year survivals were 43.8-69.9% based on recent reports [2, [5] [6] [7] . The 5-year survival for our cases was 64%. The varying 5-year survival rates may be due to the heterogeneity of stage IIB, ethnic differences, or different frequencies of the factors for stage IIB.
Large tumors (larger than 7 cm) were categorized as T3, from previous T2, in the seventh edition of TNM staging. Previous, sixth edition of TNM staging. P values are shown in the Fig. 1 . Further, it has been reported that tumors with same-lobe nodules had better prognoses than other T4 tumors that were locally advanced diseases according to the sixth edition of the TNM system [8, 9] . Therefore, in the seventh TNM system, same-lobe nodules were categorized as T3, from previous T4, a locally less-invasive disease. These newly categorized stage-IIB tumors, T3N0M0 groups (groups C and D), had slightly better prognoses than the previous stage-IIB tumors, T3N0M0 and T2aN1M0 groups (groups A and B). However, we have to note that the results do not necessarily imply that newly categorized T3 (large tumors > 7 cm, previously T2, and same-lobe nodules, previously T4) are not suitably categorized as T3. This is because we did not examine whether T3 (>7 cm or same-lobe nodules) N1M0 and T3 (>7 cm or same-lobe nodules) N2M0 were suitably categorized as stage IIIA in this study. Further study will be needed to clarify the suitability of newly categorized T3, including N factors.
In the seventh TNM staging system, some sub-categories did not change their stages. In stage IA, there are T1a and T1b categorized according to tumor size [10] . In cases of chestwall invasion, the T factor is comprised of T3a, T3b, and T3c according to their degrees of infiltration, which are all categorized as T3. M1 comprises of M1a and M1b [11] . These sub-categories are intended to be references for decision making for future TNM staging. However, there is no concept regarding 'multiple' T3 factors. In this study, we demonstrated that the number of T3 factors may influence the prognosis, although the stage is IIB. Although the frequency of cases with multiple T3 factors was low, we should take note of the fact that these populations will have poorer prognoses in the same stage-IIB NSCLC. With a large-scale case accumulation in the future, the meaning of the subdivisions by the number of T3 factors will be clarified.
We did not sub-categorize T3 chest-wall invasion by the degree of invasion, although this is now a point of focus. Some reports showed that the degree of invasion affected the prognosis [12] , while others did not [13] . Thus, there is no established theory regarding the influence of the degree of invasion. In the seventh edition of TNM staging, the possibility that the degree of invasion affected prognosis was considered, and sub-categorized as pT3a, pT3b, and pT3c, although these subgroups are all pT3. In this study, we focused on the number of T3 factors, but did not focus on the sub-categorization of T3 invasion. This was because the aim of this study was to clarify the prognosis of stage IIB, and not to clarify the degree of T3 invasive tumors.
Owing to recent advances in adjuvant therapy, adjuvant cisplatin-based chemotherapy is routinely recommended for patients with completely resected stage-II NSCLC [14] . However, the efficacy of adjuvant chemotherapy for T3N0 tumors remains unknown [15] . In this study, we could not clarify the effect of adjuvant therapy primarily due to the small size of the patient population. Further study will be needed to evaluate the efficacy of adjuvant therapy for stage IIB, particularly for T3N0 tumors.
In summary, this study has highlighted the potential prognostic value of TN factors in resected stage-IIB NSCLCs. Among four single factors, same-lobe nodules had the best prognoses, whereas T2bN1M0 had the worst prognoses. Newly categorized T3 factors (>7 cm or same-lobe nodules) showed better prognoses than previous TN factors (chestwall invasion or T2bN1M0). A multiple-T3-factors group had a poorer prognosis than a single-TN-factor group. These features have implications for therapeutic strategies, such as clinical trials or patient care, for resected stage-IIB NSCLC because the new TNM staging system does not indicate the best treatment for each NSCLC patient.
